Phibro Animal Health (PAHC) Q3 2026 earnings review
Core Margins Expand as Acquisition Growth Normalizes
Phibro delivered a strong Q3 with Revenue up 10% and Adjusted EBITDA up 11%. More importantly, management raised the lower end of its full-year guidance across all key metrics. Underneath the headline beats, the narrative is shifting: the massive inorganic growth from the October 2024 Zoetis MFA acquisition has fully annualized. As a result, top-line growth has decelerated from 40% in Q1 to 10% today. The company is now proving it can drive organic expansion and structural margin improvements, with gross margins jumping 270 bps YoY to 32.8%. However, a severe contraction in Free Cash Flow and a newly disclosed regulatory issue in Brazil present emerging risks that require monitoring.
🐂 Bull Case
Gross margin expanded 270 bps to 32.8%, proving management's ability to drive favorable product mix and capture pricing power, even as input and distribution costs rise.
Management increased the midpoint of its FY26 guidance for Revenue, Net Income, and Adjusted EBITDA, signaling strong visibility and confidence heading into the fiscal year-end.
🐻 Bear Case
Trailing twelve-month Free Cash Flow plummeted to $12.8M from $47.3M just one quarter ago. For a company carrying $740.9M in debt, this cash conversion disconnect warrants severe scrutiny.
The Performance Products segment continues to bleed, decelerating to a 17% YoY revenue decline due to weak demand for personal care ingredients.
⚖️ Verdict: 🟢
Bullish. The optical growth deceleration was expected as the Zoetis acquisition laps. The underlying organic engine (Animal Health +13%) and expanding margins reflect a high-quality quarter, despite the cash flow concerns.
Key Themes
Animal Health Core Strength
The Animal Health segment, which represents 76% of total revenue, grew a robust 13% YoY to $291.2M. The growth is broad-based: MFAs (+13%), Vaccines (+16%), and Nutritional Specialties (+8%). The legacy business and the integrated Zoetis portfolio are driving true volume and price expansion, overcoming the 'comp' wall of lapping the October 2024 acquisition.
Structural Margin Improvements
Gross margin accelerated to 32.8% (up 270 bps YoY). Even excluding prior-period noise (inventory write-offs and acquisition step-ups), adjusted gross margins still expanded by 130 bps to 33.5%. This was driven by a favorable product mix and increased average selling prices, successfully offsetting higher input costs. The 'Phibro Forward' initiative is clearly yielding bottom-line results.
Brazil Regulatory Uncertainty
Management casually disclosed a post-quarter 'regulatory development in Brazil affecting certain antimicrobial products.' Given that Phibro is highly dependent on Latin America and the MFA portfolio is their largest revenue contributor, this opaque disclosure represents a tangible and unquantified risk to FY27 projections.
Performance Products Segment Reversing
The Performance Products segment is actively decelerating. After a 7% decline in 26Q1 and a 10% decline in 26Q2, revenue dropped 17% YoY in Q3 to $18.9M. Gross profit for the segment fell $1.0M. Management continues to cite 'lower demand for ingredients used in personal care products' without presenting a clear turnaround strategy.
SG&A Growing Faster Than Revenue
While gross margins look excellent, operating leverage is being capped by SG&A expense, which grew 14% YoY ($81.0M)—outpacing the 10% revenue growth. Excluding one-time items, SG&A still grew 14%, driven primarily by increased employee-related costs in the Animal Health segment.
Other KPIs
Reversing severely. LTM Free Cash Flow dropped to $12.8M, a sharp contrast to the $47.3M reported just last quarter (26Q2) and $34.3M in 26Q1. With LTM Adjusted EBITDA at $240.7M and Net Income growing 15% YoY this quarter, the collapse in cash conversion strongly implies a massive working capital build (likely inventory or accounts receivable) that management needs to clarify.
Accelerating slightly. Up 12% YoY from $9.4M, driven by the expiration of a favorable interest rate swap agreement on $300.0M of notional debt principal. This was partially mitigated by lower baseline interest rates and higher patronage income.
Stable. Total debt sits at $740.9M against LTM Adjusted EBITDA of $240.7M. The company also upsized its revolving credit facility by $125M (to $435M total) in April 2026, providing robust liquidity despite the weak operating cash flow generation this quarter.
Guidance
Accelerating organically. The midpoint ($1.48B) was raised from the previous $1.455B, implying a strong 14% YoY growth against FY25 ($1.296B). Given the Zoetis acquisition is now in the base, this implies confidence in organic volume/pricing in Q4.
Accelerating. The midpoint ($251M) implies massive 37% YoY growth over FY25 ($183.7M). Management raised the lower end of the range, reflecting improved visibility and the realization of cost-savings from the Phibro Forward initiative.
Accelerating. Midpoint of $3.04 implies ~45% YoY growth versus FY25 ($2.09). This confirms that margin expansion and leverage are successfully dropping to the bottom line.
Key Questions
Free Cash Flow Disconnect
LTM Free Cash Flow dropped significantly to $12.8M despite robust earnings growth. Can you quantify the specific working capital headwinds (e.g., inventory build for tariffs vs. receivables) driving this cash drag, and when do you expect conversion to normalize?
Brazil Regulatory Headwind
You disclosed a recent regulatory development in Brazil affecting certain antimicrobial products. What is the precise revenue exposure of the affected products, and what is your timeline and strategy for mitigation or compliance?
Performance Products Strategy
The Performance Products segment has now posted a 17% YoY decline following consecutive quarters of weakness. Is this segment still viewed as a core asset, or are you exploring strategic alternatives given its continued drag on overall growth?